Yessica Jain
Analyst, The Fershman Journal
Yessica Jain is a sophomore at the University of Chicago, studying Business Economics and Physics. he is interested in following and writing about mergers and acquisitions, corporate strategy shifts, and innovations in the technology sector.
Yessica Jain
Analyst, The Fershman Journal
Yessica Jain is a sophomore at the University of Chicago, studying Business Economics and Physics. he is interested in following and writing about mergers and acquisitions, corporate strategy shifts, and innovations in the technology sector.
Yessica Jain
Analyst, The Fershman Journal
Yessica Jain is a sophomore at the University of Chicago, studying Business Economics and Physics. he is interested in following and writing about mergers and acquisitions, corporate strategy shifts, and innovations in the technology sector.

Yessica Jain — Articles

Yessica Jain — Articles

Yessica Jain — Articles

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto

Feb 3, 2026

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Author Image

Yessica Jain

Nov 6, 2025

Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Author Image

Yessica Jain

Nov 6, 2025

Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet

Nov 6, 2025